Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update

Annals of Oncology

Volumn 7, Issue SUPPL. 4, 1996, Pages

  Horning, S J ^a,b   Rosenberg, S A ^a   Hoppe, R T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Chemotherapy; Combined modality therapy; Hodgkin's disease; Radiation therapy; Toxicity

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0029794027     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_4.S105     Document Type: Conference Paper

References (27)

1. Canellos GP, Andersen JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478-84.
2. Bonadonna G, Valagussa P, Santoro A. Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986;104:739-46.
3. Klimo P, Connors JM. MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1174-82.
4. Santoro A, Bonadonna G, Valagussa P et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27-37.
5. Behar RA, Horning SJ, Hoppe RA. Hodgkin's disease with bulky mediastinal involvement: Effective management with com'bined modality therapy. Int J Radiat Oncol Biol Phys 1993; 25: 771-6.
6. Viviani S, Santoro A, Ragni G et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP.vs. ABVD. Eur J Cancer Clin Oncol 1995; 21: 601-5.
7. Brice P, Tredaniel J, Monsuez JJ et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 1991; 2 (Suppl 1): 73-6.
8. Steinherz LJ, Steinherz PG, Tan CTC et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-7.
9. Tucker MA, Coleman CN, Cox RS et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318: 76-81. ^
10. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949-55.
11. Horning SJ, Adhikari A, Rizk N et al. .Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study. J Clin Oncol 1994; 12:297-305..
12. Bartlett NL, Rosenberg SA, Hoppe RT et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: A preliminary report. J Clin Oncol 1995; 13:1080-8.
13. Connors JM, Klimo P, Adams G et al. MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc Am Soc Clin Oncol 1992; 11:317 (Abstr 1073).
14. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: The Milan experience. Ann Oncol 1991; 2:55-62.
15. Anselmo AP, Cartoni C, Bellantuono P et al. Risk of infertility in patients with Hodgkin's disease treated with ABVD vs. MOPP vs. ABVD/MOPP. Haematologica 1990; 75:155-8.
16. LaGrange JL, Thyss A, Caldani C et al. Toxicity of a combination of ABVD chemotherapy and mediastinal irradiation for Hodgkin's disease patients with massive initial mediastinal involvement. Bull Cancer 1988; 75:801-6.
17. Henry-Amar M, Dietrich PY. Acute leukemia after the treatment of Hodgkin's disease. Hem One Clin N Am 1993; 7:369-87.
18. Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325:1682-7.
19. Winick NJ, McKenna RW, Shuster JJ et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993; 11:209-17.
20. Hoppe RT, Colemen CN, Cox RS et al. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 1982; 59: 455-65.
21. Longo DL, Russo A, Duffey PL et al. Treatment of advancedstage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9:227-35.
22. Brizel DM, Winer EP, Prosnitz LR et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. IntJ Radiat Oncol BiolPhys 1990; 19:535-42.
23. Yahalom J, Ryu J, Straus D et al. Impact of adjuvant radiation and the pattern and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9:2193-201.
24. Diehl V, Pfreundschuh M, Loffler M et al. Chemotherapy vs. involved-field (IF) radiotherapy for consolidation of remission achieved with three double cycles of cyclophosphamide, vincristine, procarbazine, prednisone (COPP) and doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) for stages IIIB/IV Hodgkin's disease: A randomized trial of the German Hodgkin Study Group. Proc Am Soc Clin Oncol 1990; 9: 273 (Abstr 1057).
25. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment for Hodgkin's disease. J Nat Cancer Insti 1993; 85: 25-31.
26. Kaldor JM, Day NE, Clarke EA et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322:7-13.
27. Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. 1958; 53:270-83.